'Tumor response' presentation slideshows

Response Evaluation of Gastrointestinal Stromal Tumors (GIST)

931 views • 51 slides

Clinical Application of Evolving Treatment Paradigms in Advanced Breast Cancer

Expert Review of Breast Cancer Treatment. Clinical Application of Evolving Treatment Paradigms in Advanced Breast Cancer . Clifford A. Hudis, MD Chief, Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell Medical College New York, NY.

694 views • 37 slides

RESPONSE EVALUATION OF MESOTHELIOMA THERAPY

RESPONSE EVALUATION OF MESOTHELIOMA THERAPY. Dr. Muzaffer Metinta? Eski?ehir Osmangazi University Medical Faculty Department of Chest Diseases metintas@superonline.com April 2007. We want to measure tumor response:.

580 views • 37 slides

Arturo Chiti Medicina Nucleare Istituto Clinico Humanitas, Rozzano - Milano

INQUADRAMENTO DIAGNOSTICO E APPROCCIO TERAPEUTICO DEI TUMORI NEUROENDOCRINI Milano, 25 maggio 2007 La terapia radiorecettoriale: dalla diagnostica alla terapia molecolare. Arturo Chiti Medicina Nucleare Istituto Clinico Humanitas, Rozzano - Milano arturo.chiti@humanitas.it.

531 views • 29 slides

ODAC Discussion on Accelerated Approval March 12-13, 2003

566 views • 25 slides

NEW IMAGING MODALITIES IN BREAST CANCER MANAGEMENT

NEW IMAGING MODALITIES IN BREAST CANCER MANAGEMENT. Dr Rachel Boutemy. MANAGEMENT OF BC PATIENTS. High quality staging Neoadjuvant therapy: need to quantify early primary tumor response MRI: high morphological accuracy, functional potentials FDG PET: metabolic information

586 views • 25 slides

CTOS Meeting Venice, Italy 4 November 2006

Initial Results of a Multicenter, Single-Arm Phase 2 Study of AMG 706, an Oral Multikinase Inhibitor, for the Treatment of Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST).

475 views • 24 slides

Ali Shamsedddine, MD Professor of Medicine Head of Hematology-Oncology Division

No Effect on Tumor Response with Weekly Oxaliplatin Added to Standard Preoperative 5-FU/RT in locally Advanced Rectal Cancer. Ali Shamsedddine, MD Professor of Medicine Head of Hematology-Oncology Division American University of Beirut Medical Center. Challenges in treatment of rectal Cancer.

340 views • 24 slides

CTOS Meeting Venice, Italy 4 November 2006

Initial Results of a Multicenter, Single-Arm Phase 2 Study of AMG 706, an Oral Multikinase Inhibitor, for the Treatment of Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST).

456 views • 24 slides

TUMOR IMMUNOLOGY

TUMOR IMMUNOLOGY. Jan ?eromski 2011/2012. EVIDENCE FOR ANTI-TUMOR IMMUNOLOGICAL REACTIVITY. Lymphoid cell infiltrates and proliferative reaction in regional lymph nodes correlate with favourable prognosis in some tumors,

989 views • 23 slides

R. D. Issels, L.Lindner, Munich, Germany P. Hohenberger, Berlin/Mannheim, Germany

13th Annual CTOS Meeting. EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT CHEMOTHERAPY WITH OR WITHOUT REGIONAL HYPERTHERMIA (RHT).

313 views • 23 slides

The MIN mouse : (1.) Heterozygous for the highly penetrant Apc Min allele.

The MIN mouse : (1.) Heterozygous for the highly penetrant Apc Min allele. (2.) Min/Min homozygotes die at gastrulation. (3.) Mice develop numerous (50-200) adenomas in the small intestine, and few (0-3) in the colon. (4.) Death occurs around 5 months of age.

312 views • 21 slides

Protocol Investigators

ACRIN 6678 FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-small Cell Lung Cancer Study Overview. Protocol Investigators. Protocol Co-Investigators Anthony Shields, MD, PhD Karmanos Cancer Institute Karen Reckamp, MD

212 views • 21 slides

Shukla-Dave 1,2 , N. Lee 3 , Y. Wang 1 , H. Stambuk 2 , S. Karimi 2 ,

Dynamic Contrast Enhanced (DCE)-MRI as a Predictor of Response in Head & Neck Squamous Cell Carcinoma (HNSCC) : Initial Analysis. Shukla-Dave 1,2 , N. Lee 3 , Y. Wang 1 , H. Stambuk 2 , S. Karimi 2 , J.P. Shah 4 , D.G. Pfister 5 , J.A. Koutcher 1,2,5

260 views • 18 slides

Guide Lines for Management of Bladder Cancer.

Guide Lines for Management of Bladder Cancer. Mohamed S. Zaghloul Hussein Khaled Moneir Aboul Ella. Essential Work up. History taking & clinical assessment. Laboratory. CBC

437 views • 17 slides

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). Presented By Martin Schlumberger at 2014 ASCO Annual Meeting. Disclosures.

501 views • 17 slides

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma . Sternberg CN et al. ASCO 2009; Abstract 5021. (Oral Presentation). Introduction. Pazopanib, an oral angiogenesis inhibitor, has high affinity for PDGFR and VEGFR 1, 2 and 3 and also targets C-kit

544 views • 16 slides

T. Gruenberger*, H. Sorbye, M. Debois, U. Bethe, J. Primrose,

Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM) Interim results of the EORTC Intergroup randomized phase III study 40983. T. Gruenberger*, H. Sorbye, M. Debois, U. Bethe, J. Primrose,

260 views • 15 slides

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study

Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Fowler NH et al. Proc ASH 2012; Abstract 901. Background.

219 views • 8 slides